Depth of Response Predicts Survival in Unresectable Hepatocellular Carcinoma Treated with Immunotherapy: Not All Stable Disease Is Equal.
0/5 보강
APA
Kudo M (2025). Depth of Response Predicts Survival in Unresectable Hepatocellular Carcinoma Treated with Immunotherapy: Not All Stable Disease Is Equal.. Liver cancer, 14(4), 357-364. https://doi.org/10.1159/000546698
MLA
Kudo M. "Depth of Response Predicts Survival in Unresectable Hepatocellular Carcinoma Treated with Immunotherapy: Not All Stable Disease Is Equal.." Liver cancer, vol. 14, no. 4, 2025, pp. 357-364.
PMID
40672438 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study.
- Lancet Commission 2025 Calls for Urgent Global Action: 60% of Liver Cancers Are Preventable.
- Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150.
- Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography: A Potential Imaging Biomarker for Predicting Response to Combination Immunotherapy in Hepatocellular Carcinoma.
- First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
- Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab.
- Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.
- An Effective Case of Radiofrequency Ablation with the Combination of Durvalumab and Tremelimumab Treatment for Hepatocellular Carcinoma: A Case Report.
- Prognostic Nutritional Index Predicts Outcomes in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab: A Propensity Score-matched Analysis.
- Lymphocyte-Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis.